Currently, risk-assessments with various prognostic and predictive markers are used for indication of systemic treatment, like tumour grade and nodal status for general systemic treatment choice, hormonal receptors for hormonal treatment, and HER2 expression for immunotherapy. This evidence concerns the gene NR4A1 and neoplasm.